However, high TMB and increased PD-L1 expression together represent key characteristics of an immunogenic tumor that has developed PD-1 axis mediated adaptive immune resistance, which may be used to select patients for treatment with anti-PD-1 or anti-CTLA-4 ICIs (50, 52). This evidence concerns the gene CTLA4 and neoplasm.